Clinical Utility of Wilms' Tumor 1 Monitoring in Patients with Myeloid Malignancy and Prior Allogeneic Hematopoietic Stem Cell Transplantation.

Abstract

Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) is 1 of the standard treatments for myeloid malignancy, relapse remains a major obstacle to cure. Early detection of relapse by monitoring of minimal residual disease (MRD) may enable us to intervene pre-emptively and potentially prevent overt relapse. Wilms' tumor 1 (WT1) is well known… (More)
DOI: 10.1016/j.bbmt.2017.06.007

Topics

Cite this paper

@article{Ino2017ClinicalUO, title={Clinical Utility of Wilms' Tumor 1 Monitoring in Patients with Myeloid Malignancy and Prior Allogeneic Hematopoietic Stem Cell Transplantation.}, author={Kazuko Ino and Shigeo Fuji and Kinuko Tajima and Takashi Tanaka and Keiji Okinaka and Yoshihiro Inamoto and Saiko Kurosawa and Sung-Won Kim and Naoyuki Katayama and Takahiro Fukuda}, journal={Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation}, year={2017}, volume={23 10}, pages={1780-1787} }